RegulatoryOfficial
European Commission authorises Alexion's Klygefa (gefurulimab) in new marketing authorisation
🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026
Commission Decision (2026) 8207 of 12 November 2026 grants Alexion Europe SAS a marketing authorisation for Klygefa, following EMA procedure EMEA/H/C/006558/0000.
The European Commission has granted a new marketing authorisation for Klygefa (gefurulimab), held by Alexion Europe SAS. The decision, Commission Decision (2026) 8207, is dated 12 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.
More Regulatory
All →
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
🇨🇦 Health Canada · Wed 18 Nov 2026
FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease
🇺🇸 FDA · Wed 18 Nov 2026
INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown
🇵🇹 INFARMED · Wed 18 Nov 2026
Commission publishes minutes of SCHEER working group meeting on brain stimulators
🇪🇺 European Commission (DG SANTE) · Wed 18 Nov 2026
AIFA reminds sponsors how to pay Annual Safety Report evaluation fee
🇮🇹 AIFA · Wed 18 Nov 2026